✦ LIBER ✦

A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer

✍ Scribed by The Abarelix Study Group, ; Trachtenberg, John; Gittleman, Marc; Steidle, Christopher; Barzell, Winston; Friedel, William; Pessis, Dennis; Fotheringham, Nick; Campion, Marilyn; Garnick, Marc B.

Book ID: 122219737
Publisher: Lippincott Williams and Wilkins
Year: 2002
Tongue: English
Weight: 89 KB
Volume: 167
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(05)65175-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 3, multicenter, open-label, rand

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

✍ David McLeod; Norman Zinner; Kevin Tomera; Donald Gleason; Nick Fotheringham; Ma 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Prolonged treatment with three-weekly do

Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan

✍ Kazuo Nishimura,Norio Nonomura… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 271 KB

Effectiveness, pharmacokinetics, and saf

Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: A phase III, open-label, international multicenter study

✍ Michael Marberger; Amir V Kaisary; Neal D. Shore; Gary S. Karlin; Claudio Savuls 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Randomized, Multicenter, Open-Label Phas

Randomized, Multicenter, Open-Label Phase II Study of Gemcitabine plus Single-Dose Versus Split-Dose Carboplatin in the Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

✍ Wolfgang Schuette; Thomas Blankenburg; Claus-Peter Schneider; Ludwig Fischer von 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 142 KB

Safety and Efficacy of Once-Daily Hydrom

Safety and Efficacy of Once-Daily Hydromorphone Extended-Release Versus Twice-Daily Oxycodone Hydrochloride Controlled-Release in Chinese Patients With Cancer Pain: A Phase 3, Randomized, Double-Blind, Multicenter Study

✍ Yu, Shiying; Shen, Wei; Yu, Lu; Hou, Yanyan; Han, John; Richards, Henry M. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 518 KB

Randomized open-label non-comparative mu

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study

✍ Auliac, J.B.; Chouaid, C.; Greiller, L.; Monnet, I.; Le Caer, H.; Falchero, L.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 484 KB